Moleculin Announces Exercise of Warrants for $6.8 Million Gross Proceeds

Core Viewpoint - Moleculin Biotech, Inc. has announced agreements for the immediate exercise of existing warrants, which will generate approximately $6.5 million in gross proceeds for the company [1][4]. Group 1: Financial Transactions - The company has entered into agreements for the immediate exercise of warrants to purchase up to 727,969 shares at an exercise price of $6.63 per share and 316,360 shares at an exercise price of $6.3219 per share [1]. - In exchange for the immediate exercise of these warrants, the company will issue new unregistered warrants for an aggregate of up to 2,610,823 shares at an exercise price of $6.63 per share, exercisable upon shareholder approval for a term of five years [3]. - The transaction is expected to close on or about December 11, 2025, subject to customary closing conditions, with net proceeds intended for working capital and general corporate purposes [4]. Group 2: Company Overview - Moleculin Biotech, Inc. is a late-stage pharmaceutical company focused on developing drug candidates for hard-to-treat tumors and viruses [1][7]. - The company's lead program, Annamycin, is designed to avoid multidrug resistance and cardiotoxicity, currently in development for relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma lung metastases [7]. - The company has initiated the MIRACLE Trial, a pivotal Phase 3 trial evaluating Annamycin in combination with cytarabine for the treatment of relapsed or refractory AML, following a successful Phase 1B/2 study [8]. Group 3: Pipeline and Development - Moleculin is also developing WP1066, an immune/transcription modulator targeting brain tumors and other cancers, along with a portfolio of antimetabolites including WP1122 for potential treatment of pathogenic viruses and certain cancer indications [9].